The use of gallium-67 scintigraphy to monitor tumor response rates and predict long-term clinical outcome in patients with lymphoma

Clinical Lymphoma

Volumn 5, Issue 1, 2004, Pages 56-61

  Tuli, Mahmoud M ^a   Al Shemmari, Salem H ^b   Ameen, Reem M ^b   Al Muhanadi, Shihab ^a   Al Huda, Fawaz Abu ^a   Ballani, Nasser ^b   Khoshi, M ^a   Al Enezi, Farha ^a   Bajciova, Viera ^a   Mottl, Hubert ^a  

^a KUWAIT CANCER CONTROL CENTER   (Kuwait)

^b KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Disease monitoring; Functional imaging; Optimization of treatment; Outcome prediction; Tumor response

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GALLIUM CITRATE GA 67; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SCINTISCANNING; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG EFFICACY; DRUG UPTAKE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; PATIENT COMPLIANCE; PATIENT MONITORING; PREDICTION; PROGNOSIS; SCHOOL CHILD; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 4344714044     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.n.011     Document Type: Article

References (40)

1. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster Group studies. J Clin Oncol 1994; 12:899-908.
2. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage - a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995; 13:359-372.
3. Patte C, Michon J, Frappaz D, et al. Therapy of burkitt and B cell acute lymphoblastic leukemia and lymphoma: experience with the LMB protocols of the SFOP (French Pediatric Oncology Society) in children and adults. Baillieres Clin Haematol 1994; 7:339-348.
4. Magrath IT. The treatment of pediatric lymphomas: paradigms to plagiarize? Ann Oncol 1997; 8(suppl 1):7-14.
5. Ekert H, Waters KD, Smith PJ, et al. Treatment with MOPP or ChIVPP chemotherapy only for all ages of childhood Hodgkin's disease. J Clin Oncol 1988; 6:1845-1850.
6. Gehan EA, Sullivan MP, Fuller LM, et al. The intergroup Hodgkin's disease in children: A study of stages I and II. Cancer 1990; 65:1429-1437.
7. Oberlin O, Leverger G, Pacquement H, et al. Low-dose radiotherapy therapy and reduced chemotherapy in childhood Hodgkin's disease: The experience of the French Society of Pediatric Oncology. J Clin Oncol 1992; 16:897-906.
8. Hudson MM, Greenwald C, Thompson E, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease J Clin Oncol 1993; 11:100-108.
9. Schellong G, Hornig-Franz I, Rath B, et al. Reducing radiotherapy dosage to 20-30 Gy in combined chemo-/radiotherapy of Hodgkin's disease in childhood: A report of the cooperative DAL-HD-87 therapy study. Klin Padiatr 1994; 206:253-262.
10. Schellong G, Bramswig JH, Hornig-Franz I et al. Hodgkin's disease in children: Combined modality treatment for stages IA, IB, and IIA-Results in 356 patients of the German/Austrian Pediatric Study Group. Ann Oncol 1994; 5:113-115.
11. Hutchinson RJ, Fryer CJ, Davis PC, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group phase III trial. J Clin Oncol 1998; 16:897-906.
12. Armata J, Balwierz W, Moryl-Bujakowska A, et al. Childhood stage IV Hodgkin's disease: Therapeutic results of the Polish Pediatric Leukemia/Lymphoma Study Group. Med Pediatr Oncol 1999; 33:382-387.
13. Shipp MA, Harrington DP. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-994.
14. Link MP, Shuster JJ, Donaldson SS et al. Treatment of children and young adults with early stage non-Hodgkin's lymphoma. N Engl J Med 1997; 337:1259-1266.
15. Loeffler M, Hasenclever D, Sextro M, et al. Meta analysis of chemotherapy versus combination treatment trials in Hodgkin's disease: International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 1998; 16:818-829.
16. Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiotherapy therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group Study. J Clin Oncol 1997; 15:2769-2779.
17. Nachman JB, Sposto R, Herzog P et al. Randomized comparison of low dose involved -field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20:3765-3771.
18. Gordon L, Harrington D, Anderson J, et al. Comparison of second-generation combination chemotherapy regimen (m-BACOP) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327:1342-1349.
19. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-1006.
20. Shipp MA, Harrington DP. A predictive model for aggressive non-Hodgkin's lymphoma. The International Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-994.
21. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339:1506-1514.
22. Armitage JO, Weisenberger DD, Hutchins M, et al. Chemotherapy for diffuse large cell lymphoma. Rapidly responding patients have more durable remission. J Clin Oncol 1986; 4:160-164.
23. Verdonck LF, Van Putten WLJ, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slow responding patients with aggressive non-Hodgkin's lymphoma. 1995. N Engl J Med 332:1045-1051.
24. Engelhard MPM, Brittinger G, et al. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: Updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol 1991; 2:177-180.
25. Iosilevsky G, Front D, Bettman L, et al. Uptake of Gallium-67 citrate and [2-3H] deoxyglucose in the tumor model, following chemotherapy and radiotherapy. J Nucl Med 1985; 26:278-282.
26. Israel O, Front D, Lam M, et al. Gallium-67 Imaging in Monitoring lymphoma Response to Treatment: Cancer 1988; 61:2439-2443.
27. Front D, Ben-Haim S, Israel O, et al. Lymphoma: Predictive value of Ga-67 scintigraphy after therapy. Radiology 1992; 182:359-363.
28. Hagemeister FB, Purugganan R, Podoloff DA, et al. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol 1994; 5(suppl 2): S59-S63.
29. King SC, Reiman RJ, Prosnitz LR. Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease. J Clin Oncol 1994; 12:306-311.
30. Vose JM, Bierman PJ, Anderson JR, et al. Single-photon emission computed tomography gallium imaging versus computed tomography: Predictive value in patients undergoing high-dose chemotherapy and autologus stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1996; 14:2473-2479.
31. Salloum E, Brandt DS, Caride VJ, et al. Gallium scans in the management of patients with Hodgkin's disease: A study of 101 patients. J Clin Oncol 1997; 15:518-527.
32. Bogart JA, Chung CT, Mariados NF, et al. The value of gallium imaging after therapy for Hodgkin's disease. Cancer 1998; 82:754-759.
33. Wylie BR, Southee AE, Joshua DE et al. Gallium scanning in the management of mediastinal Hodgkin's disease. Eur J Haematol 1989; 42:344-347.
34. Kaplan WD, Jochelson MS, Herman TS, et al. Gallium-67 imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990; 8:1966-1970.
35. Janicek M, Kaplan W, Neuberg D, et al. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkins lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15:1631-1637.
36. Gasparini M, Bombardieri E, Castellani M, et al. Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma. J Nucl Med 1998; 39:1586-1590.
37. Front D, Bar-Shalom R, Mor M, et al. Hodgkin's disease. Prediction of outcome with Ga-67 scintigraphy after one cycle of chemotherapy. Radiology 1999; 210:487-491.
38. Front D, Bar-Shalom R, Mor M, et al. Aggressive non-Hodgkin lymphoma: Early prediction of outcome with Ga-67 scintigraphy. Radiology 2000; 214:253-257.
39. Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: current status. Oncologist 2003; 8:438-447.
40. Kostakglu L, Leonard JP, Kuji I, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94:879-888.